Aceclofenac vs paracetamol in the management of symptomatic osteoarthritis of the knee: a double-blind 6-week randomized controlled trial1,2

Osteoarthritis and Cartilage

Volumn 15, Issue 8, 2007, Pages 900-908

  Batlle Gualda, E ^a   Roman Ivorra J ^b   Martin Mola E ^c   Carbonell Abello J ^d   Linares Ferrando, L F ^e   Tornero Molina, J ^f   Raber Bejar A ^g   Fortea Busquets, J ^g  

^a HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE   (Spain)

^b Hospital Dr Pesset   (Spain)

^c HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^d Del Mar University   (Spain)

^e HOSPITAL UNIVERSITARIO VIRGEN DE LA ARRIXACA   (Spain)

^f HOSPITAL UNIVERSITARIO DE GUADALAJARA   (Spain)

^g NONE   (Spain)

Author keywords

Aceclofenac; Controlled clinical trial; Osteoarthritis; Paracetamol; Treatment

Indexed keywords

ACECLOFENAC; ANTACID AGENT; HISTAMINE H2 RECEPTOR ANTAGONIST; PARACETAMOL; PLACEBO; PROTON PUMP INHIBITOR;

ACCIDENTAL INJURY; ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONJUNCTIVAL HEMORRHAGE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ACTIVITY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FUNCTIONAL STATUS; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; INFECTION; KNEE OSTEOARTHRITIS; KNEE PAIN; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MULTICENTER STUDY; MUSCULOSKELETAL PAIN; MYALGIA; PAIN ASSESSMENT; PARALLEL DESIGN; PATIENT ASSESSMENT; PERIPHERAL EDEMA; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SHORT FORM 36; SIDE EFFECT; SPAIN; TREATMENT DURATION; VISUAL ANALOG SCALE;

ACETAMINOPHEN; ADULT; AGED; ANALGESICS, NON-NARCOTIC; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; DICLOFENAC; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; OSTEOARTHRITIS, KNEE; TREATMENT OUTCOME;

EID: 34547657726     PISSN: 10634584     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.joca.2007.02.008     Document Type: Article

References (51)

1. Carmona L., Ballina J., Gabriel R., and Laffon A. The burden of musculoskeletal diseases in the general population of Spain: results from a national survey. Ann Rheum Dis 60 (2001) 1040-1045
2. Brandt K.D., and Bradley J.D. Should the initial drug used to treat osteoarthritis pain be a nonsteroidal antiinflammatory drug? (Editorial). J Rheumatol 28 (2001) 467-473
3. Jordan K.M., Arden N.K., Doherty M., Bannwarth B., Bijlsma J.W.J., Dieppe P., et al. EULAR Recommendations 2003: an evidence based approach to the management of knee osteoarthritis: Report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis 62 (2003) 1145-1155
4. Eccles M., Freemantle N., and Mason J. North of England evidence based guideline development project: summary guideline for non-steroidal anti-inflammatory drugs versus basic analgesia in treating the pain of degenerative arthritis. The North of England Non-Steroidal Anti-Inflammatory Drug Guideline Development Group. BMJ 317 (1998) 526-530
5. American College of Rheumatology Subcommittee on osteoarthritis Guidelines. Recommendations for the medical management of osteoarthritis of the hip and knee: 2000 update. Arthritis Rheum 43 (2000) 1905-1915
6. Case J.P., Baliunas A.J., and Block J.A. Lack of efficacy of acetaminophen in treating symptomatic knee osteoarthritis: a randomized, double-blind, placebo-controlled comparison trial with diclofenac sodium. Arch Intern Med 163 (2003) 169-178
7. Pincus T., Koch G., Lei H., Mangal B., Sokka T., Moskowitz R., et al. Patient Preference for Placebo, Acetaminophen (paracetamol) or Celecoxib Efficacy Studies (PACES): two randomised, double blind, placebo controlled, crossover clinical trials in patients with knee or hip osteoarthritis. Ann Rheum Dis 63 (2004) 931-939
8. Zhang W., Jones A., and Doherty M. Does paracetamol (acetaminophen) reduce the pain of osteoarthritis? A meta-analysis of randomised controlled trials. Ann Rheum Dis 63 (2004) 901-907
9. Neame R., Zhang W., and Doherty M. A historic issue of the Annals: three papers examine paracetamol in osteoarthritis. Ann Rheum Dis 63 (2004) 897-900
10. Miceli-Richard C., Le Bars M., Schmidely N., and Dougados M. Paracetamol in osteoarthritis of the knee. Ann Rheum Dis 63 (2004) 923-930
11. Bradley J.D., Brandt K.D., Katz B.P., Kalasinski L.A., and Ryan S.I. Comparison of an antiinflammatory dose of ibuprofen, an analgesic dose of ibuprofen, and acetaminophen in the treatment of patients with osteoarthritis of the knee. N Engl J Med 325 (1991) 87-91
12. Bradley J.D., Katz B.P., and Brandt K.D. Severity of knee pain does not predict a better response to an antiinflammatory dose of ibuprofen than to analgesic therapy in patients with osteoarthritis. J Rheumatol 28 (2001) 1073-1076
13. Bradley J.D., Brandt K.D., Katz B.P., Kalasinski L.A., and Ryan S.I. Treatment of knee osteoarthritis: relationship of clinical features of joint inflammation to the response to a nonsteroidal antiinflammatory drug or pure analgesic. J Rheumatol 19 (1992) 1950-1954
14. Williams H.J., Ward J.R., Egger M.J., Neuner R., Brooks R.H., Clegg D.O., et al. Comparison of naproxen and acetaminophen in a two-year study of treatment of osteoarthritis of the knee. Arthritis Rheum 36 (1993) 1196-1206
15. Pincus T., Koch G.G., Sokka T., Lefkowith J., Wolfe F., Jordan J.M., et al. A randomized, double-blind, crossover clinical trial of diclofenac plus misoprostol versus acetaminophen in patients with osteoarthritis of the hip or knee. Arthritis Rheum 44 (2001) 1587-1598
16. Geba G.P., Weaver A.L., Polis A.B., and Dixon M.E. Schnitzer TJ for the VACT Group. Efficacy of rofecoxib, celecoxib, and acetaminophen in osteoarthritis of the knee. JAMA 287 (2002) 64-71
17. Lee C., Straus W.L., Balshaw R., Barlas S., Vogel S., and Schnitzer T.J. A comparison of the efficacy and safety of nonsteroidal antiinflammatory agents versus acetaminophen in the treatment of osteoarthritis: a meta-analysis. Arthritis Rheum (Arthritis Care Res) 51 (2004) 746-754
18. Scott D.L., and Kingsley G. Translating research into practice: acetaminophen in osteoarthritis revisited. J Rheumatol 30 (2004) 199-202
19. Courtney P., and Doherty M. Key questions concerning paracetamol and NSAIDs for osteoarthritis. Ann Rheum Dis 61 (2002) 67-73
20. Okie S. Raising the safety bar. The FDA's Coxib Meeting (Editorial). N Engl J Med 352 (2005) 1283-1285
21. Graham D.J., Campen D., Hui R., Spence M., Cheetham C., Levy G., et al. Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study. Lancet 365 (2005) 475-481
22. Johnsen S.P., Larsson H., Tarone R.E., McLaughlin J.K., Nograd B., Friis S., et al. Risk of hospitalization for myocardial infarction among users of rofecoxib, celecoxib and other NSAIDs. Arch Intern Med 165 (2005) 978-984
23. Grau M., Guasch J., Montero L., Felipe A., Carrasco E., and Juliá S. Pharmacology of the potent new non-steroidal anti-inflammatory agent aceclofenac. Arzneim Forsch Drug Res 41 (1991) 1265-1276
24. Hinz B., Rau T., Auge D., Werner U., Ramer R., Rietbrock S., et al. Aceclofenac spares cyclooxygenase 1 as a result of limited but sustained biotransformation to diclofenac. Clin Pharmacol Ther 74 (2003) 222-235
25. Perez Busquier M., Calero E., Rodriguez M., Castellon Arce P., Bermudez A., Linares L.F., et al. Comparison of aceclofenac with piroxicam in the treatment of osteoarthritis. Clin Rheumatol 16 (1997) 154-159
26. Giorgianni G., Ottaviani C., Soliano A., and Campi A. Efficacy and tolerability of aceclofenac versus ketoprofen in the treatment of rheumatoid arthritis. Curr Ther Res 51 (1992) 1-10
27. Batlle-Gualda E., Figueroa M., Ivorra J., Raber A., and the Aceclofenac Indomethacin Study Group. The efficacy and tolerability of aceclofenac in the treatment of patients with ankylosing spondylitis: a multicenter controlled clinical trial. J Rheumatol 23 (1996) 1200-1206
28. Dooley M., Spencer C.M., and Dunn C.J. Aceclofenac: a reappraisal of its use in the management of pain and rheumatic disease. Drugs 61 (2001) 1351-1378
29. Legrand E. Aceclofenac in the management of inflammatory pain. Expert Opin Pharmacother 5 (2004) 1347-1357
30. Kellgren J.H., and Lawrence J.S. Radiographic assessment of osteo-arthrosis. Ann Rheum Dis 16 (1957) 494-502
31. Hochberg M.C., Chang R.W., Dwosh I., Lindsey S., Pincus T., and Wolfe F. The American College of Rheumatology 1991 revised criteria for the classification of global functional status in rheumatoid arthritis. Arthritis Rheum 35 (1992) 498-502
32. Doyle D.V., Dieppe P.A., Scott J., and Huskisson D.C. An articular index for the assessment of osteoarthritis. Ann Rheum Dis 40 (1981) 75-78
33. Lequesne M.G., Mery C., Samson M., and Gerard P. Indexes of severity for osteoarthritis of the hip and knee. Validation-Value in comparison with other assessment tests. Scand J Rheumatol Suppl 65 (1987) 85-89
34. Fries J.F., Spitz P., Kraines G., and Holman H.R. Measurement of patient outcome in arthritis. Arthritis Rheum 23 (1980) 137-145
35. Esteve-Vives J., Batlle-Gualda E., and Reig A. Grupo para la Adaptación del HAQ a la Población Española. Spanish version of the Health Assessment Questionnaire (HAQ): reliability, validity and transcultural equivalency. J Rheumatol 20 (1993) 2116-2122
36. Bellamy N., Buchanan W.W., Goldsmith C.H., Campbell J., and Stitt L.W. Validation study of WOMAC: A health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee. J Rheumatol 15 (1988) 1833-1840
37. Batlle-Gualda E., Esteve-Vives J., Piera M.C., Hargreaves R., and Cutts J. Adaptación transcultural del cuestionario WOMAC específico para artrosis de rodilla y cadera. Rev Esp Rheumatol 26 (1999) 38-45
38. Ware J.E., and Sherbourne C.D. The MOS 36-item short-form health survey (SF-36): I. Conceptual framework and item selection. Med Care 30 (1992) 473-483
39. Alonso J., Prieto L., and Antó J.M. La versión española del SF-36 Health Survey (Cuestionario de Salud SF-36): un instrumento para la medida de los resultados clínicos. Med Clin (Barc) 104 (1995) 771-776
40. Bellamy N., Carette S., Ford P.M., Kean W.F., le Riche N.G.H., Lussier A., et al. Osteoarthritis antirheumatic drug trials II. Tables for calculating sample size of clinical trials. J Rheumatol 19 (1992) 444-450
41. Hochberg Y. A sharper Bonferroni procedure for multiple tests of significance. Biometrika 75 (1988) 800-802
42. Pincus T., Swearingen C., Cummins P., and Callahan L.F. Preference for nonsteroidal antiinflammatory drugs versus acetaminophen and concomitant use of both types of drugs in patients with osteoarthritis. J Rheumatol 27 (2000) 1020-1027
43. Wolfe F., Zhao S., and Lane N. Preference for nonsteroidal antiinflammatory drugs over acetaminophen by rheumatic disease patients: a survey of 1,799 patients with osteoarthritis, rheumatoid arthritis, and fibromyalgia. Arthritis Rheum 43 (2000) 378-385
44. Peris F., Bird H.A., Serni U., Irani M.S., Diaz C., and Gijón-Baños J. Treatment compliance and safety of aceclofenac versus standard NSAIDs in patients with common arthritic disorders: a meta-analysis. Eur J Rheumatol Inflamm 16 (1996) 37-45
45. Peris F., Martinez E., Badia X., and Brosa M. Iatrogenic cost factors incorporating mild and moderate adverse events in the economic comparison of aceclofenac and other NSAIDs. Pharmacoeconomics 19 (2001) 779-790
46. Laporte J.R., Ibanez L., Vidal X., Vendrell L., and Leone R. Upper gastrointestinal bleeding associated with the use of NSAIDs: newer versus older agents. Drug Saf 27 (2004) 411-420
47. Llorente Melero M.J., Tenias Burillo J.M., and Zaragoza Marcet A. Comparative incidence of upper gastrointestinal bleeding associated with individual non-steroidal anti-inflammatory drugs. Rev Esp Enferm Dig 94 (2002) 7-18
48. Pendleton A., Arden N., Dougados M., Doherty M., Bannwarth B., Bijlsma J.W.J., et al. EULAR recommendations for the management of knee osteoarthritis: report of a task force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis 59 (2000) 936-944
49. García Rodríguez L.A., and Hernández-Díaz S. Relative risk of upper gastrointestinal complications among users of acetaminophen and nonsteroidal anti-inflammatory drugs. Epidemiology 12 (2001) 570-576
50. Rahme E., Pettitt D., and LeLorier J. Determinants and sequelae associated with utilization of acetaminophen versus traditional nonsteroidal anti-inflammatory drugs in an elderly population. Arthritis Rheum 46 (2002) 3046-3054
51. Abramson S.B. Et tu, acetaminophen? (Editorial). Arthritis Rheum 46 (2002) 2831-2835